Based on the significant unmet need in Alzheimers disease as well as a number of indicative data points, we felt we had a responsibility to explore semaglutides potential, despite a low likelihood of success, Martin Holst Lange, chief scientific officer at Novo Nordisk said in a press release
Consistent habits, dose adjustments, and awareness of side effects all play a role in reaching and keeping goals
doi: 10.3389/fendo.2024.1372992 Received 19 January 2024 Accepted 20 May 2024 Published 25 June 2024 Volume 15 - 2024 Edited by Devjit Tripathy, The University of Texas Health Science Center at San Antonio, United States Reviewed by Adrian Soto-Mota, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mexico Anapaula Sommer Vinagre, Federal University of Rio Grande do Sul, Brazil Updates Copyright 2024 Buenaventura-Collazos, Garca-Ramos, Balczar-Valencia, Aguilar-Londoo, Coronel-Restrepo, Monsalve-Arango, Cuesta-Castro and Ramrez-Rincn
Constipation rates vary by formulation and dose, with approximately 5-15% of patients on Ozempic and 11-24% of patients on Wegovy reporting constipation
